Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

ClinicalTrials.gov ID: NCT01927419

Public ClinicalTrials.gov record NCT01927419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Study identification

NCT ID: NCT01927419
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 142 participants

Conditions and interventions

Conditions

Interventions

Nivolumab Drug
Ipilimumab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 22, 2013
Primary completion: Jul 23, 2014
Completion: Feb 25, 2021
Last update posted: Mar 17, 2022

2013 – 2021

United States locations

U.S. sites: 19
U.S. states: 16
U.S. cities: 16

Facility	City	State	ZIP	Site status
San Francisco Oncology Associates	San Francisco	California	94115	—
Orlando Health Inc	Orlando	Florida	32806	—
University Of Louisville Medical Center, Inc., Dba	Louisville	Kentucky	40202	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Massachusetts General Hospital	Boston	Massachusetts	02215	—
Washington University School Of Medicine	St Louis	Missouri	63110	—
Comprehensive Cancer Centers Of Nevada	Las Vegas	Nevada	89148	—
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
University Of New Mexico Cancer Center	Albuquerque	New Mexico	87131	—
NYU Clinical Cancer Center	New York	New York	10016	—
Memorial Sloan Kettering Nassau	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27710	—
The Christ Hospital	Cincinnati	Ohio	45219	—
Oregon Health & Science University	Portland	Oregon	97239	—
St. Luke's Hospital	Easton	Pennsylvania	18045	—
GHS Cancer Institute	Greenville	South Carolina	29615	—
Huntsman Cancer Institute	Salt Lake City	Utah	84112	—
University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01927419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2022 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01927419 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →